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de-nova lesions located at the ostium of the LAD that underwent DCA before stenting 
(DCA+S) in 46 cases or that were treated with stenting alone (S) in 71 cases. Results: 
Techmcal success in DCA+S and S group was 95.6% and 95.7%, respectively, p=O.69. 
No differences were observed in in-hospital major adverse events (MACE, i.e. death, 
non-Q and Q-wave myocardial infarction, need of revascularization) (4.3 % for DCA+S 
and 4.2% for S respectively, p=n.s). Angiographic results are summarized in table. All 
patients had &months clinical follow-up: MACE rate was lower (even though not signifi- 
catively) in DCA+S group than in S group, (20.0% vs. 35.5%, p=O.O61). The angiographic 
follow-up was performed for 95 patients after 5.9e2.2 months and showed a significantly 
lower binary restenosis rate for DCA+S group in comparison to S group (10.8% vs. 
33.3%, p=O.O15). Conclusions: DCA before stenting in de-now ostial LAD lesions is safe 
and is associated to a high rate of technical success. Follow-up data indicate that DCA+S 
in this setting provides a significantly larger MLD and lowers the incidence of restenosis if 
compared to stenting alone. 
* = p<O.OS for compansons between the two groups (independent samples t-test) 
Basal ref, mm, Basal MLD, 
n=ll7 mm, n=ll7 
CCA 3.4tO.5 1.1&S 
+S 
Acute Gain, 
mm, n=ll7 
2.4ztO.6 
Late loss, 
mm, n=95 
0.6a0.6 
Loss index, 
n=95 
0.33*0.35* 
S 3.4a0.4 1.2+0.5 2.1*0.7 1.0+0.7 0.59*0.42 
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Background: Studies have reported excellent short and mid-term outcome of unpro- 
tected left main coronary artery (ULMCA) stenting with only 8.15% clinical restenosis 
rate. The predictors of restenosis after ULMCA stenting especially in high surgical risk 
patients have not been well established. 
Methods: We present the complete follow-up results in 188 consecutive patients under- 
going ULMCA stenting at our center from January 1998 to June 2002. Based on Parson- 
net surgical risk score. patients were divided into high surgical risk (n=ll2) with a score 
~15 and low surgical risk (n=76) for <I5 score. 
Results: All patients underwent stenting, 65% after rotablatlon, and procedure was suc- 
cessful in all with one in-hospital death due to CVA. Mean age was 82i6 yrs, mean LVEF 
31*14%, GP inhibitors use 76%. and elective IABP in 38%. Stenosis location: ostium in 
25%, body/distal in 60%, and bifurcation in 15%. CK-MB elevation occurred in 21%, with 
z-5x normal in 4%. Vascular complications occurred in 3%. All but one patients were dis- 
charged alive at a mean duration of 5*4 days. At a mean one-year follow-up there were 
16 deaths: 8 cardiac (4 Cl-IF, 2 MI, 1 arrhythmia, 1 stent thrombosis), 8 non-cardiac (4 
CVA, 2 pneumonia, 1 hyperkaliemia, 1 neoplasm). A total of 26 patients (15%) required 
repeat intaivention for recurrence of angina. heart failure, or Dositive non-invasive test- 
p=O.OOOl for PCI YS CABG respectively. 
Conclusions: The immediate and medium term survival followng unprotected LMCA 
stenting was equivalent to CABG. The longer term outcome of PCI was limited by the 
need for TLR. Stenting offers an excellent alternative to CABG in patients with relative 
contraindications to surgery. 
1076-l 92 Clinical Outcome After Multivessel Stenting in Diabetic 
Versus Nondiabetic Patients: Impact of Restenosis and 
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BackgrounctDiabetes Mellitus has a negative impact on outcome after percutaneous 
interventions (PCI). We examined our experience of multivessel PCI to determine the 
factors that limit the effectiveness of PCI in diabetic (DM) patients. 
Methods and Results: Between Jan 2000 and Dee 2001 we performed multivessel PCI 
in 99 DM with 254 treated lesions versus 239 non-DM patients with 620 treated lesions. 
Both groups were well matched as regard clinical and lesions characteristics except that 
DM patients had more renal insufficiency (6.1% vs 0.8%). Number of diseased segments 
treated (2.820.9 vs 2.66iO.79) and stents implanted per patient (2.3iO.6 vs 2.47kO.72) 
were similar in the 2 groups. Angiographic and clinical results after a mean follow up of 
433+275 days were: 
Non-diabetic p value 
Diabetic 
QCA: Reference diameter (mm) 3.17*0.5 3.19+0.6 NS 
Final MLD 3.19iO.68 3.2lkO.6 NS 
Final diameter stenosis (%) 1.26 +8.1 2.1k7.6 NS 
In-hospital DeathflVR 0 0 
to imDact the climcal outcome of diabetic oatients after PCI. 
NS 
In-hospital Ml 7.1 % 3% NS 
In-hospital MACE 7.1 % 3.3 % NS 
Follow-up Death 4 % 3 % NS 
Follow-up Ml 0 % 3 % NS 
Follow-up TVR 29 % 16 % 0.03 
MACE 38 % 23 % 0.04 
The need for TVR was due to disease progression in 57% of DM patients and 26% in non 
DM patients p=O.O2. The event-free survival was 65*0.5% vs 8020.2 at 1 year and 
55+0.6% vs 7lkO.3 at 2 years (p=O.Ol) for DM and non DM respectively. 
Conclusion:The medium and longer term success of multivessel PCI in diabetic 
patients is limited principally by the need for repeat revascularization which are per- 
formed not only for restenosis but also for disease progression. Consequently, even if 
drug eluting stent technology can eliminate restenosis, disease progression will continue 
mg. One patient underwent CABG at follow-up. Protocol mandated angiography was 
done in 48 asymptomatic patients and none had >70% stenosis of LMCA. On multivari- 
ate analysis, independent predictors of restenosls were bifurcation lesion intervention 
(OR 4.2; 95% Cl 2.2.6.8), diabetes (OR 2.4; 95% Cl 1.8-3.2). and reference vessel diam- 
eter ~3.75 mm (OR 3.2; 95% Cl 2.2-4.3). Event free suwival (Ml, revasculaiization, or 
death) was 72% in high-nsk versus 91% in low-risk patients (p=O.Ol). 
COnCluSiOn: The present analysis suggests that ULMCA stenting is a viable optlon wtth 
good long-term outcome, especially in patients with low risk for CABG. With introduction 
of coated stents. stenting of non-biturcation ULMCA lesion may have equal outcome as 
CABG and can be recommended. 
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Background: Coronary artery bypass surgery (CABG) is the treatment of choice for 
patients with significant disease of the left main (LMCA) coronary artery. Recent data has 
confirmed both the safety and efficacy of percutaneous coronary revascularizatlon (PCI) 
and Stent implantation for LMCA disease in selected patients. To date no trial comparing 
CABG vs PCI has included patients with LMCA disease. We have evaluated in hospital 
and mid term outcomes in patients wth significant (>50%) LMCA disease treated either 
by CABG or PCI. 
Methods and Results: Between Jan 2000 and Dee 2001, 187 patients underwent elec- 
tive revascularization for symptomatic LMCA disease: 115 CABG and 72 PCI. PCI and 
CABG patients were well matched in terms of diabetes (10% vs 14%. NS), previous Ml 
(7.5% vs 8%, NS) and mean LVEF (57+14% YS 59tl3%, N.S.). However, the PCI group 
had patients at higher risk, EuroScore was 4.9 vs 2.5, p=O.OOOl. There were more 
females (10.7 vs 6.4 %, p=O.O02), older patients (74+9 vs 66+9, p=O.OOl), more obstrc- 
tive lung disease (19 vs 1.7%, p=O.OOOl) and more renal impairment (5.3% vs 1.6%, 
p=O.O03) in PCI compared to CABG. In hospital events were : 3 deaths (1 PCI, 2 CABG, 
NS). 7 Ml (4 PCI, 3 CABG, NS) 1 TLR (0 PCI, 1 CABG, NS) and 2 strokes ( 0 PCI, 2 
CABG. NS).Total in-hospital event rate was equal in both groups (4.9% vs 4.9%. NS). At 
a mean follow up of 415* 215 days, there were 16 further deaths (10 PCI vs 6 CABG, 
p=O,O6). only 9 were cardiac (5 PCI vs 4 CABG, NS), 2 Ml (1 PCI vs 1 CABG. NS), 16 
TLR (13 PCI YS 3 CABG, p=O.OOl). EuroScore was an univariate predictor of cardiac 
mortality: 5.5+ 2.5 (cardiac death) vs 3.3 t 2.1 (survivors), p=O.OOl. Kaplan-Meier analy- 
sis revealed cardiac death free survival at 1 year of 92+0.3% vs 94 +0.3% (mean + SEE), 
p=NS and MACE (death, MI, TLR) free survival of 6620.5% YS 86+0.4%, log rank 
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Background: Unprotected left main (LM) coronary stenting is now an accepted alterna- 
tive to coronary surgery with excellent immediate and long term outcomes in selected 
patients. However, the impact of the anatomical location of the target stenosis in the LM 
on climcal outcome is unknown. We set out to assess the impact of target lesion location 
on clinical outcome in unprotected LM stenting 
Methods and Results: Between Jan 1994 and Aug 2002 we performed unprotected LM 
stenting on 214 consecutive patients. There were 167 (80%) male patients, mean age 
74* 8 years, 24% diabetic, 12% renal insufficiency, mean LVEF 57* 14%. The anatomi- 
cal location of the target lesion in the LM was: ostial 26%, mid-shaft 21% and distal bifur- 
cation lesions 53%. Initial procedural success was 100%. The in-hospital MACE rate was 
7.7% (7 deaths, 8 Ml and 1 TLR). Follow up on 197 (98%) was completed for a mean of 
23+ 20 months. Total MACE rate during follow up was 31% (38 deaths, 5 Ml and 35 
TLR). There was a significant difference, by Kaplan Meier analysis, in MACE rates at 1 
and 5 years comparing the distal (D) and non-distal (ND) (ostial and mid shaft) lesions: 
61% and 39% for D and 78% and 62% for ND respectively, p<O.OOOl There was an 
increased mortality in the D group: 27% vs 14%, ~~0.03 although cardiac mortality was 
not different 19% vs 1 l%, NS. There was no difference in the calculated Euroscore 
between patients with D and ND lesions: 4.9+2.5 vs 4.7+2 p=NS. There was also a sig- 
nificant difference in the TLR rates beh.veen the 2 groups: 27 vs 8, p=O.O02 for D vs ND 
respectively. 
COnCluSion: Unprotected LM stenting can be performed with excellent lmmedmte and 
long term outcomes in ostial and mid-shaft lesions. Stenting of unprotected distal LM 
lesions is associated with a significantly Increased risk of death and TLR The majomy of 
the events was concentrated in the first 6 months following procedure suggesting an 
important role of in stent restenosis. This issue may be overcome in the near future by 
the use of drug eluting stents. 
